Palavras-chave
Escetamina
Depressão pós-parto
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar o uso da cetamina e seu derivado, escetamina, na prevenção da depressão pós-parto. Métodos: Revisão integrativa da literatura, conduzida conforme as recomendações PRISMA e orientada pela estratégia PICO. A busca foi realizada nas bases PubMed, SciELO e Biblioteca Virtual em Saúde. Foram aplicados como filtros o período de publicação entre 2021-2025 e delineamento do tipo ensaio clínico randomizado (ECR). Resultados: Foram incluídos 13 ECRs que avaliaram diferentes esquemas de administração de cetamina ou escetamina, predominantemente no contexto perioperatório de cesarianas, com foco na prevenção da DPP. Observou-se concentração geográfica dos estudos, majoritariamente realizados na China, e heterogeneidade quanto às doses, vias de administração, momentos de aplicação e instrumentos utilizados para avaliação dos desfechos depressivos. Considerações finais:A análise dos ECRs indica que a cetamina e a escetamina têm sido investigadas como estratégias farmacológicas promissoras na prevenção da depressão pós-parto, especialmente no contexto perioperatório. Contudo, evidencia-se a necessidade de pesquisas adicionais, conduzidas em diferentes cenários e com protocolos padronizados, para melhor definir a eficácia, a segurança e o papel dessas substâncias na promoção da saúde mental materna no período perinatal.
Referências
ALBUQUERQUE RN, LEITE MGS. Fatores associados à depressão gestacional: uma Revisão integrativa. Revista Saúde Multidisciplinar, 2023; 14(1): 3-9.
ALIPOOR M, et al. The effect of ketamine on preventing postpartum depression. Journalof Medicineand Life, 2021; 14(1): 87-92.
APA – Associação Americana de Psiquiatria. Manual diagnóstico e estatístico de transtornos mentais: DSM-5-TR. 5. ed. rev. Porto Alegre: Artmed, 2023; 1152p.
BOERMA T, et al. Global epidemiology of use of and disparities in caesarean sections. The Lancet, 2018; 392(10155): 1341-1348.
CAMPOS CA, et al. Fatores de risco, proteção, diagnóstico e tratamento da depressão pós-parto no contexto da atenção primária. Revista Eletrônica Acervo Saúde, 2021; 13(1): e5410.
CASTRO ACP, et al. Avaliação da depressão no puerpério imediato e tardio. Revista Eletrônica Acervo Saúde, 2024; 24(12), e18741.
CHEN Y, et al. Perioperative adjunctive esketamine for postpartum depression among women undergoing elective cesarean delivery: a randomized clinical trial. JAMA Network Open, 2024; 7(3): e240953.
CHEN J, ZHAO N. Recent advances in drug development and regulatory science in China. Therapeutic Innovation & Regulatory Science, 2018; 52(6): 739-750.
DENNIS C-L, DOWSWELL T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database of Systematic Reviews, 2013; 2: 1-161.
DI VINCENZO JD, et al. The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review. Journal of Psychiatric Research, 2021; 137: 232-241.
FDA – Food & Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. FDA, 10 out. 2023. Disponível em: https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine. Acessoem: 28 dez. 2025.
GUAN L-N, et al. Research progress in the treatment of postpartum depression. Cellular and Molecular Neurobiology, 2025; 45(1): 1-12.
HAN Y, et al. S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial. BMC Anesthesiology, 2022; 22(1): 1-7.
JAWAD MY, et al. The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2022; 21(6): 841-852.
LI S, et al. Effects of ketamine and esketamine on preventing postpartum depression after cesarean delivery: A meta-analysis. Journal of Affective Disorders, 2024a; 351: 720-728.
LI S, et al. Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial. BMC Anesthesiology, 2024b; 24(1): 1-10.
LING B, et al. Effect of single intravenous injection of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial. BMC Pharmacology and Toxicology, 2023; 24(1): 1-8.
LIU Q-R, et al. Effects of perioperative use of esketamine on postpartum depression risk in patients undergoing cesarean section: a randomized controlled trial. Journal of Affective Disorders, 2023; 339: 815-822.
LUO M, et al. Effects of esketamine on post-partum depression in patients with different personality types undergoing caesarean section: randomised controlled trial. ActasEspañolas de Psiquiatría, 2025; 53(4): 766-777.
MARTINS FM, et al. Fatores desencadeantes e sintomas associados à depressão pós-parto. BrazilianJournalofImplantologyand Health Sciences, 2024; 6(2): 222-242.
MOSOLOVA D. Pharmaceutical companies turn to jurisdictions with simpler regulatory regimes. Financial Times, 21 out. 2024. Disponível em: https://www.ft.com/content/3d861acb-8e7d-4157-b845-81124254da8a. Acessoem: 28 dez. 2025.
O'HARA MW, MCCABE JE. Postpartum depression: current status and future directions. Annual Review of Clinical Psychology, 2013; 9(1): 379-407.
REN L, et al. Intraoperative esketamine and postpartum depression among women with cesarean delivery: a randomized clinical trial. JAMA Network Open, 2025; 8(2): e2459331.
SHANG Y, et al. The effect of low-dose esketamine on maternal depression after cesarean delivery. Journal of Psychosomatic Obstetrics &Gynecology, 2025; 46(1): 2527659.
SHEN J, et al. The effect of low-dose esketamine on pain and post-partum depression after cesarean section: a prospective, randomized, double-blind clinical trial. Frontiers in Psychiatry, 2023; 13: 1038379.
TAN R, et al. Current landscape of innovative drug development and regulatory support in China. Signal Transduction and Targeted Therapy, 2025; 10(1): 1-36.
TRICCO AC, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Annals of Internal Medicine. 2018; 169(7): 467-473.
WAN X, et al. The effect of a subclinical dose of esketamine on depression and pain after cesarean section: A prospective, randomized, double-blinded controlled trial. Medicine, 2024; 103(44): e40295.
WANG S-M, et al. Rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis. Clinical Psychopharmacology and Neuroscience, 2021; 19(2): 341.
WANG S, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ, 2024; 385: e078218.
WANG W, et al. Effects of esketamine on analgesia and postpartum depression after cesarean section: a randomized, double-blinded controlled trial. Medicine, 2022; 101(47): e32010.
WANG W, et al. Effect of pre-administration of esketamine intraoperatively on postpartum depression after cesarean section: a randomized, double-blinded controlled trial. Medicine, 2023; 102(9): e33086.
WHO – World Health Organization. ICD-11 - International Classification of Diseases 11th Revision. Disponível em: https://icd.who.int/en. Acesso em: 26 dez. 2025.
XU L-L, et al. RETRACTED: Efficacy and safety of esketamine for supplemental analgesia during elective cesarean delivery: a randomized clinical trial. JAMA Network Open, 2023; 6(4): e239321.
XU S, et al. Esketamine pretreatment during cesarean section reduced the incidence of postpartum depression: a randomized controlled trail. BMC Anesthesiology, 2024; 24(1): 1-10.